Navigation Links
Solos Endoscopy Finishes the 3rd Quarter Strong
Date:10/21/2011

BOSTON, Oct. 21, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40.  The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company recently announced its intentions to donate 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.

About Solos Endoscopy, Inc.:Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.CONTACT:

Amanda Segerstenrsegersten@solosendoscopy.com
'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
2. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
3. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
4. Solos Endoscopy to Reduce Debt by Over $620,000
5. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
6. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
7. Solos Endoscopy, Inc. To Launch New Corporate Website
8. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
9. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
10. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
11. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):